{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T20:34:49Z","timestamp":1740170089320,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s43441-023-00607-0","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T16:01:31Z","timestamp":1704384091000},"page":"387-394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics of Anticancer Drugs Approved Under the Accelerated Approval Program in the US: Success or Failure in Converting to Regular Approval"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6364-9075","authenticated-orcid":false,"given":"Yoshihiro","family":"Oda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Narukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"607_CR1","unstructured":"Food and Drug Administration Safety and Innovation Act, 21 USC \u00a7301. July 9, 2012. https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-112publ144\/pdf\/PLAW-112publ144.pdf. Accessed 20 Apr 2023."},{"key":"607_CR2","unstructured":"US Food and Drug Administration. Guidance for Industry: Expedited Programs for Serious Conditions Drugs and Biologics. May 2014. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/expedited-programs-serious-conditions-drugs-and-biologics. Accessed 20 Apr 2023."},{"issue":"18","key":"607_CR3","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1056\/NEJMp2104846","volume":"384","author":"JA Beaver","year":"2021","unstructured":"Beaver JA, Pazdur R. \u201cDangling\u201d accelerated approvals in oncology. N Engl J Med. 2021;384(18):e68.","journal-title":"N Engl J Med"},{"issue":"10","key":"607_CR4","doi-asserted-by":"publisher","first-page":"e213177","DOI":"10.1001\/jamahealthforum.2021.3177","volume":"2","author":"RE Suchs","year":"2021","unstructured":"Suchs RE, Gavulic KA, Donohue JM, et al. Recent trends in medicaid spending and use of drugs with US Food and Drug Administration accelerated approval. JAMA Health Forum. 2021;2(10):e213177.","journal-title":"JAMA Health Forum"},{"key":"607_CR5","unstructured":"European Medicines Agency (EMA). Guideline on the Evaluation of Anticancer Medicinal Products in Man. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-anticancer-medicinal-products-man-revision-5_en.pdf. Accessed 20 Mar 2023."},{"key":"607_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s10120-013-0274-6","volume":"17","author":"K Shitara","year":"2014","unstructured":"Shitara K, Matsuo K, Muro K, et al. Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer. Gastric Cancer. 2014;17:362\u201370.","journal-title":"Gastric Cancer"},{"issue":"2","key":"607_CR7","doi-asserted-by":"publisher","first-page":"100398","DOI":"10.1016\/j.esmoop.2022.100398","volume":"7","author":"BJ Solomon","year":"2022","unstructured":"Solomon BJ, Loong HH, Summers Y, et al. Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations. ESMO Open. 2022;7(2):100398.","journal-title":"ESMO Open"},{"issue":"6","key":"607_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","volume":"4","author":"JA Beaver","year":"2018","unstructured":"Beaver JA, Howie LJ, Pelosof L, et al. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol. 2018;4(6):849\u201356.","journal-title":"JAMA Oncol"},{"key":"607_CR9","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","volume":"179","author":"B Gyawali","year":"2019","unstructured":"Gyawali B, Hey SP, Kesselheim AS. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern Med. 2019;179:906\u201313.","journal-title":"JAMA Intern Med"},{"key":"607_CR10","unstructured":"Withdrawn \/ Cancer Accelerated Approvals. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/withdrawn-cancer-accelerated-approvals. Accessed 31 Dec 2022."},{"issue":"10122","key":"607_CR11","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, Dur\u00e1n I, Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748\u201357.","journal-title":"Lancet"},{"issue":"10142","key":"607_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123\u201333.","journal-title":"Lancet"},{"issue":"21","key":"607_CR13","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369\u201379.","journal-title":"J Clin Oncol"},{"issue":"12","key":"607_CR14","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, Heijden MS, Castellano D, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1574\u201388.","journal-title":"Lancet Oncol"},{"issue":"5","key":"607_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","volume":"32","author":"DR Spigel","year":"2021","unstructured":"Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol. 2021;32(5):631\u201341.","journal-title":"Ann Oncol"},{"issue":"1","key":"607_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77\u201390.","journal-title":"Lancet Oncol"},{"key":"607_CR17","unstructured":"Oncology (Cancer) \/ Hematologic Malignancies Approval Notifications. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/oncology-cancer-hematologic-malignancies-approval-notifications. Accessed 31 Dec 2022."},{"key":"607_CR18","unstructured":"Verified Clinical Benefit\/Cancer Accelerated Approvals. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/verified-clinical-benefit-cancer-accelerated-approvals. Accessed 31 Dec 2022."},{"key":"607_CR19","unstructured":"Ongoing \/ Cancer Accelerated Approvals.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/ongoing-cancer-accelerated-approvals. Accessed 31 Dec 2022."},{"key":"607_CR20","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov. Accessed 31 Dec 2022."},{"issue":"3","key":"607_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"607_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40\u201351.","journal-title":"Nat Biotechnol"},{"key":"607_CR23","unstructured":"US Food and Drug Administration. Guidance for industry: Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics. March 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-considerations-support-accelerated-approval-oncology-therapeutics. Accessed 30 July 2023."}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-023-00607-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-023-00607-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-023-00607-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T18:16:19Z","timestamp":1707329779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-023-00607-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1007\/s43441-023-00607-0","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"type":"print","value":"2168-4790"},{"type":"electronic","value":"2168-4804"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"3 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest. YO is an employee of Chugai Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}